Anti NMDA Receptor Encephalitis, Autoimmune Encephalitis, Herpetic Encephalitis
Conditions
Brief summary
Herpes Simplex Virus encephalitis is the most common infectious encephalitis, with an estimated annual incidence of 1 / 250,000 to 1 / 500,000 in industrialized countries. Despite a widely used antiviral treatment, the prognosis remains poor with a mortality of 5 to 20% and a considerable morbidity rate. One of the contributing factors of bad prognosis is the development of encephalitis mediated by autoantibodies, most often directed against NMDA receptors, in the weeks following viral encephalitis. The description of this pathology is recent, the pathophysiology of this process remains poorly understood, and the management of these patients is not yet codified.
Interventions
Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Clinical autoimmune encephalitis with anti-NMDA antibodies and documented by CBA in the CSF * After a herpetic encephalitis documented by a positive viral PCR for HSV in the CSF * Without age limit
Exclusion criteria
- No respect of inclusion criteria
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Details of clinical, biological, imaging, therapeutic characteristics and patient's evolution. | at 6 and 12 months | Retrospective collection of clinical, diagnostic and therapeutic data, evolution at 6 and 12 months. |
Countries
France
Contacts
Primary ContactJérôme Honnorat, PhD
Backup ContactGéraldine PICARD
Outcome results
None listed